A model of subcutaneous pramlintide pharmacokinetics and its effect on gastric emptying: Proof-of-concept based on populational data

C Furió-Novejarque, I Sala-Mira, JL Díez… - Computer Methods and …, 2024 - Elsevier
Pramlintide, an amylin analog, has been coming up as an agent in type 1 diabetes dual-
hormone therapies (insulin/pramlintide). Since pramlintide slows down gastric emptying, it …

[HTML][HTML] Analysis on the contribution of glucagon receptors to glucose dynamics in type 1 diabetes

C Furió-Novejarque, I Sala-Mira, AG Ranjan… - IFAC Journal of Systems …, 2024 - Elsevier
The glucagon effect is understudied in type 1 diabetes (T1D) simulators, without a clear
consensus on the pharmacodynamics of glucagon over glucose. Glucagon receptors …

A Type 2 Diabetes Simulator for Multiscale Glycemic Dynamics

AN Shahidehpour - 2024 - search.proquest.com
Diabetes mellitus affects more than 30 million people in the United States and more than
400 million people worldwide. It is estimated that 90-95% of these people have type 2 …

Model-Informed Medical Technology Development: A simulation study to evaluate the impact of model-based clinical study design and analysis on effect size …

MM Carvalho Lima Vieira Araujo - 2024 - diva-portal.org
Randomisedcontrolledtrials (RCT) areconsideredthegoldstandardforassessing the efficacy
and safety of medical interventions. However, RCTs face unique challenges when applied to …

Contributions to Glucagon and Pramlintide Pharmacokinetics and Pharmacodynamics Modeling for Multi-Hormone Artificial Pancreas Systems

C Furió Novejarque - 2024 - riunet.upv.es
[ES] La regulación de los niveles de glucosa en el cuerpo humano es el resultado de la
secreción coordinada de hormonas. La Diabetes Tipo 1 (DT1) es una enfermedad crónica …